Hikma Pharmaceuticals PLC HIK shares slipped 1.68% to £19.86 Monday, on what proved to be an all-around rough trading session ...

Hikma Pharmaceuticals PLC (Hikma, Group), the multinational generic pharmaceutical company, announces the approval of KLOXXADO ® (naloxone HCl) Nasal Spray 8 mg, by Health Canada for the treatment of ...

Hikma Pharmaceuticals (HKMPF) announces the approval of KLOXXADO Nasal Spray 8 mg, by Health Canada for the treatment of known or suspected ...

Hikma Pharmaceuticals PLC closed 11.86% below its 52-week high of £23.60, which the company reached on February 13th.

Shares of Hikma Pharmaceuticals stock opened at GBX 2,123.65 ($27.45) on Friday. The stock has a market capitalization of £5.89 billion, a P/E ratio of 20.84, a PEG ratio of 2.38 and a beta of 0.41.

Collegium Pharmaceutical Inc. is a specialty pharma ... The company has secured a generic agreement with Hikma for production of the drug post-exclusivity period. Sales in 2024 were $100.7 million ...

Hikma was founded in Jordan and is the second largest drugmaker in the Middle East and north Africa by sales, after French pharmaceutical company Sanofi. Mishlawi said weight loss drugs are very ...

Axsome Therapeutics has entered into a settlement agreement with Hikma resolving patent litigation related to Axsome’s product Sunosi (solriamfetol). The litigation, which is pending in the ...

Axsome Therapeutics AXSM announced that it has entered into a settlement agreement with Hikma Pharmaceuticals related to patents for its narcolepsy drug, Sunosi (solriamfetol). The settlement ...

today announced that it has entered into a settlement agreement with Hikma Pharmaceuticals USA, Inc. (Hikma) resolving patent litigation related to Axsome's product Sunosi ® (solriamfetol).